IO-112 is under clinical development by IO Biotech and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase I drugs for Metastatic Melanoma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IO-112’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IO-112 overview

IO-112 is under development for the treatment of essential thrombocythemia and polycythemia vera, relapsed/refractory metastatic solid tumors including breast cancer, colorectal cancer, head and neck cancer squamous cell carcinoma, melanoma, ovarian cancer, and transitional cell cancer (urothelial cell cancer). It is administered through subcutaneous route.. It is developed based on T-win technology. The drug candidate is an immune modulatory vaccine containing a single arginase derived peptide targeting Arginase 1 (ARG1).

IO Biotech overview

IO Biotech is a biotechnology company, which develops disruptive immune modulating anti-cancer drugs. The company is investigating IO102 vaccine, against non-small cell lung cancer (NSCLC); IO130, a PD-L1 inhibitor targeting basal cell carcinoma of the skin; IO112 vaccine, to treat solid tumors; IO140, an immune modulatory vaccine containing a single CCL22 derived peptide, against ovarian cancer; and IO160, a neo antigen vaccine to treat myeloproliferative neoplasms (MPN). It utilizes T-win technology platform to discover, design, and validate new immune modulating vaccine candidates. The company is a spin off from the Center for Cancer Immune Therapy (CCIT), University of Copenhagen Herlev Hospital. IO Biotech is headquartered in Copenhagen, Denmark.

For a complete picture of IO-112’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.